This past April I reported that Vaxart, a small San Francisco vaccine biotech, was ready to start dosing volunteers with its experimental vaccine against norovirus, aka, the stomach flu, in Phase Ib studies (See
ACSH relies on donors like you. If you enjoy our work, please contribute.
Make your tax-deductible gift today!
Popular articles
ACSH Podcasts
